Home
Covid-19
Tools
Introduction to the Tools
Model Government Use Licences
Model Uses of Paragraph 7 or “LDC Waiver”
Special Compulsory Licences for Export of Medicines
Options for Regional Economic Communities
Voluntary Licences
TRIPS Flexibilities Database
Resources
Briefs & Briefing Documents
Publications
Tools
Useful Links
All Resources
Blog
About
Search
Medicines Law & Policy
Research and resources on intellectual property and health
Home
Covid-19
Tools
Introduction to the Tools
Model Government Use Licences
Model Uses of Paragraph 7 or “LDC Waiver”
Special Compulsory Licences for Export of Medicines
Options for Regional Economic Communities
Voluntary Licences
TRIPS Flexibilities Database
Resources
Briefs & Briefing Documents
Publications
Tools
Useful Links
All Resources
Blog
About
Tag: covid-19
New WHO-UNITAID briefing paper: Improving Access to Covid-19 Treatments
Kaitlin Mara
-
April 12, 2023
Protecting Public Health through Technology Transfer: The Unfulfilled Promise of the...
Ellen 't Hoen
-
March 16, 2023
ML&P’s Comments to the Intergovernmental Negotiating Body (INB) on the Zero...
Ellen 't Hoen
-
February 28, 2023
Medicines price transparency: Ground still left to cover
Katrina Perehudoff
-
February 3, 2023
Wrapping up 2022 with some noteworthy medicines, law and policy events
Medicines Law & Policy
-
December 22, 2022
Seven recommendations for sharing intellectual property, know-how and technology – report...
Medicines Law & Policy
-
July 18, 2022
WTO Covid-19 TRIPS Decision: Some observations
Medicines Law & Policy
-
June 17, 2022
Proposed TRIPS waiver a hollow diplomatic compromise with little practical impact
Medicines Law & Policy
-
April 12, 2022
The US NIH will share technology with WHO to fight the...
Medicines Law & Policy
-
March 3, 2022
With technology transfer, 120 companies in low- and middle-income countries could...
Kaitlin Mara
-
February 15, 2022
1
2
3
...
5
Page 1 of 5
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Ok
 This work is licensed under Creative Commons.